Navigation Links
Horizons AMI trial data to be presented at TCT 2007
Date:10/15/2007

WASHINGTON, DC OCTOBER 15, 2007 -- The Cardiovascular Research Foundation (CRF) will release results of its landmark research study, HORIZONS AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) at the nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C. The study is designed to examine the safety and effectiveness of stents and anticoagulants in heart attack patients undergoing angioplasty.

The HORIZONS AMI trial data will be presented at a press conference on Wednesday, October 24 at 8:40 am. The results will be presented as a late breaking trial on Wednesday, October 24 at 10:50 am.

This is a landmark trial, which will help set guidelines for drug and stent therapy during primary angioplasty in patients with heart attacks for many years to come, said Gregg W. Stone, MD, Chairman of the Cardiovascular Research Foundation and Professor of Medicine, Columbia University Medical Center.

While previous studies of drug-eluting stents have often focused on their use in patients with stable or unstable chest pain, this is the largest study to focus on the appropriate use of anticoagulation medications and drug-eluting stents in patients experiencing the highest risk form of heart attack (ST-elevation myocardial infarction).

Usually, angioplasty is associated with an excess of bleeding in heart attack patients, Dr. Stone said. However, using the anticoagulant bivalirudin with angioplasty in patients with stable coronary artery disease instead of heparin and glycoprotein IIb/IIIa inhibitors reduces bleeding, which has been associated with greater long-term survival. In the HORIZONS AMI trial, we have sought to determine whether using bivalirudin in patients with a heart attack, who undergo angioplasty, provides the same benefit.

This study should determine if bivalirudin use is as efficacious as the standard anticoagulant therapy, without causing excess bleeding in these acutely ill patients with a heart attack undergoing angioplasty, Dr. Mehran, Medical Director of the Data Coordinating and Analysis Center at CRF stated. She and her team conducted this study under an Investigational Device Exemption (IDE) from the Food and Drug Administration.

The HORIZONS AMI trial enrolled over 3600 patients presenting to hospitals in 11 countries with a heart attack. More than 120 national and international interventional cardiology centers are participating in the trial. Patients undergoing angioplasty were randomly assigned to receive either the standard anticoagulant unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor or bivalirudin alone. The patients are to be followed for five years.

Thirty-day outcome data will be presented, the primary endpoint of the study.

Comparison of Drug-Eluting Stents to Bare-Metal Stents Underway Patients enrolled in the HORIZONS AMI trial were also randomly assigned to receive either Taxus drug-eluting stents or a bare-metal stent. Data on this portion of the study also a landmark comparison of drug-eluting stents to bare-metal stents will be available next year.


'/>"/>

Contact: Irma Damhuis
idamhuis@crf.org
212-851-9187
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Man against HIV – new vaccine ready for human trials
2. FDA approves Phase 0 trial which tests experimental drugs on humans
3. Male contraceptive in trial
4. How do patients benefit of clinical trials
5. Glenmark’s new molecule to go through trial
6. Clinical trials need to be more frank
7. First head-to-head trials of once weekly Fosamax and Actonel therapies
8. Hormone Replacement Therapy increases the risk of endometrial cancer
9. Atrial fibrillation predicts for acute ischaemic stroke
10. Spray on contraceptive clears Phase I trial
11. The Indian Government has given the nod to conduct Human volunteer trials inorder to develop preventive AIDS vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/24/2017)... ... September 24, 2017 , ... The Tuscany Resort on Grace Bay in ... Provo's premier boutique resorts, is planning on re-opening the resort on October 1st. ... Irma and more recently Hurricane Maria, and the staff and landscaping crews were fast ...
(Date:9/24/2017)... ... ... Bible: The Other Sheep”: the ceremonial laws of Moses and the Holy Law of God ... published author, Maurice Caines. Maurice Caines resides in the sunny isle of Florida, but ... Seventh-day Adventist Church for many years. He was previously a member of the Anglican ...
(Date:9/22/2017)... ... September 22, 2017 , ... On Sunday, September 24, hundreds will gather ... Florence Joyner, still considered the fastest woman of all time. Flo Jo passed ... Joyner, will sing the National Anthem. Mary was a contestant on the 2012 ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... Pennsylvania, is pleased to offer in-home and online newborn sleep consultations . ... has on the body,” says company owner Courtney Zentz, a pediatric sleep professional, ...
(Date:9/22/2017)... KS (PRWEB) , ... September 22, 2017 , ... ... Plus, a nutritional supplement produced by Native Remedies that helps promote pancreatic health ... priority for many individuals. However, some prescription-based approaches can have negative side effects, ...
Breaking Medicine News(10 mins):
(Date:9/13/2017)... has been named the official orthopedic and sports medicine ... 2018 College Football Playoff (CFP) National Championship to be played ... Atlanta, Georgia . OrthoAtlanta is proud to be ... many activities leading up to, and including the national championship ... OrthoAtlanta serves ...
(Date:9/9/2017)... NEW YORK , Sept. 8, 2017 ... largest independent supplier of medical equipment, supplies, drugs, ... that it has entered into an agreement to acquire ... surgical equipment based in Holtsville, New York ... which specializes in supplying new and emerging medical practices, ...
(Date:9/7/2017)... NuvoAir (formerly called Pond Healthcare Innovation), ... partnership with Novartis Pharma AG to distribute NuvoAir,s spirometry technology ... leading mobile spirometry platform and Novartis, commitment to address the ... ... ...
Breaking Medicine Technology: